Doxorubicin-loaded micelles in tumor cell-specific chemotherapy

Аlmajidi, Yasir Q.; Kadhim, Mustafa M.; Alsaikhan, Fahad; Jalil, Abduladheem Turki; Sayyid, Nidhal Hassan; Ramírez‐Coronel, Andrés Alexis; Jawhar, Zanko Hassan; Gupta, Jitendra; Nabavi, Noushin; Yu, Wei; Ertaş, Yavuz Nuri

doi:10.1016/j.envres.2023.115722

Cited by 24 publications

(10 citation statements)

References 166 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As a traditional clinical anticancer drug, DOX induced apoptosis by two well-known pathways: (1) intercalating with DNA to disrupt the topoisomerase-II-mediated DNA repairing mechanism. 18,19 (2) Generating H 2 O 2 to rupture DNA strands and damage of cellular membranes and proteins. 20,21 Although the copper pool existing in mitochondria significantly decreased the produced H 2 O 2 , 24 DOX could still produce a high cell killing effect through the disruption of the topoisomerase-II-mediated DNA repairing mechanism.…”

Section: Resultsmentioning

confidence: 99%

“…To be specific, DOX could induce effective chemotherapy through two main pathways: (1) intercalating with DNA to disrupt the topoisomerase-II-mediated DNA repair mechanism. 18,19 (2) Generating H 2 O 2 to rupture DNA strands and damage cellular membranes and proteins. 20,21 Since copper-depletion therapy depends on intracellular ROS generation, DOX could enhance copper-depletion therapy through H 2 O 2 generation.…”

Section: Introductionmentioning

confidence: 99%

“…When taken up by tumor cells, MSN-TPP/BNA-DPA targeted mitochondria and deprived copper ions to cause mitochondria damage, reactive oxygen species (ROS) accumulation and reduced ATP production, thus inducing intensive apoptosis. Meanwhile, DOX was released from the DOX-loaded MSN-TPP/BNA-DPA (DOX@MSN-TPP/BNA-DPA) for chemotherapy through the well-known pathways 18,19,[25][26][27][28] and enhancing ROS accumulation through H 2 O 2 prodution. 20,21,[29][30][31] Taken together, the synergy of enhanced copperdepletion therapy and enhanced DOX-mediated chemotherapy significantly improved the therapeutic outcomes of cancer treatment.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Smart design of a therapeutic nanoplatform for mitochondria-targeted copper-depletion therapy combined with chemotherapy

Hu,

Gong,

Liu

et al. 2023

J. Mater. Chem. B

View full text Add to dashboard Cite

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Smart design of a therapeutic nanoplatform for mitochondria-targeted copper-depletion therapy combined with chemotherapy

Hu,

Gong,

Liu

et al. 2023

J. Mater. Chem. B

View full text Add to dashboard Cite

show abstract

“…Although there have been advancements in the progress of cancer drugs, it is evident that cytotoxic chemotherapy will remain the fundamental approach to treating cancer. , Nevertheless, the current chemotherapies are associated with nonselective drug delivery, which leads to adverse effects and toxicity that limit their efficacy. , This calls for a fresh approach to treatment and the development of distinct therapeutic methodologies. Innovative biomimetic NPs with multiple functions have been created to improve the effectiveness of chemotherapy drugs and overcome the restrictions. , These versatile nanocarriers possess the ability to transform the treatment of diverse types of cancer by utilizing the strategy of concealing themselves in T cell membrane.…”

Section: Cancer Therapymentioning

confidence: 99%

T Cell and Natural Killer Cell Membrane-Camouflaged Nanoparticles for Cancer and Viral Therapies

Ozsoy,

Mohammed,

Jan

et al. 2024

ACS Appl. Bio Mater.

Self Cite

View full text Add to dashboard Cite

Extensive research has been conducted on the application of nanoparticles in the treatment of cancer and infectious diseases. Due to their exceptional characteristics and flexible structure, they are classified as highly efficient drug delivery systems, ensuring both safety and targeted delivery. Nevertheless, nanoparticles still encounter obstacles, such as biological instability, absence of selectivity, recognition as unfamiliar elements, and quick elimination, which restrict their remedial capacity. To surmount these drawbacks, biomimetic nanotechnology has been developed that utilizes T cell and natural killer (NK) cell membrane-encased nanoparticles as sophisticated methods of administering drugs. These nanoparticles can extend the duration of drug circulation and avoid immune system clearance. During the membrane extraction and coating procedure, the surface proteins of immunological cells are transferred to the biomimetic nanoparticles. Such proteins present on the surface of cells confer several benefits to nanoparticles, including prolonged circulation, enhanced targeting, controlled release, specific cellular contact, and reduced in vivo toxicity. This review focuses on biomimetic nanosystems that are derived from the membranes of T cells and NK cells and their comprehensive extraction procedure, manufacture, and applications in cancer treatment and viral infections. Furthermore, potential applications, prospects, and existing challenges in their medical implementation are highlighted.

show abstract

“…Some examples include multifunctional synergistic delivery, site-specific delivery, co-drug delivery nanosystems, etc. [257][258][259][260]. Studies have also demonstrated nanoencapsulation targeted therapeutics to bypass MDR mechanisms associated with TME and CSC, and have also shown it to modulate metabolic reprogramming repair, and DNA repair pathways within the cancer cells and TME [261][262][263][264][265][266][267].…”

Section: Targeting Tumor Bioenergetics and Resistant Niches Through N...mentioning

confidence: 99%

Cancer Bioenergetics and Tumor Microenvironments—Enhancing Chemotherapeutics and Targeting Resistant Niches through Nanosystems

Farhana

Alsrhani

Khan

et al. 2023

Cancers

View full text Add to dashboard Cite

Cancer is an impending bottleneck in the advanced scientific workflow to achieve diagnostic, prognostic, and therapeutic success. Most cancers are refractory to conventional diagnostic and chemotherapeutics due to their limited targetability, specificity, solubility, and side effects. The inherent ability of each cancer to evolve through various genetic and epigenetic transformations and metabolic reprogramming underlies therapeutic limitations. Though tumor microenvironments (TMEs) are quite well understood in some cancers, each microenvironment differs from the other in internal perturbations and metabolic skew thereby impeding the development of appropriate diagnostics, drugs, vaccines, and therapies. Cancer associated bioenergetics modulations regulate TME, angiogenesis, immune evasion, generation of resistant niches and tumor progression, and a thorough understanding is crucial to the development of metabolic therapies. However, this remains a missing element in cancer theranostics, necessitating the development of modalities that can be adapted for targetability, diagnostics and therapeutics. In this challenging scenario, nanomaterials are modular platforms for understanding TME and achieving successful theranostics. Several nanoscale particles have been successfully researched in animal models, quite a few have reached clinical trials, and some have achieved clinical success. Nanoparticles exhibit an intrinsic capability to interact with diverse biomolecules and modulate their functions. Furthermore, nanoparticles can be functionalized with receptors, modulators, and drugs to facilitate specific targeting with reduced toxicity. This review discusses the current understanding of different theranostic nanosystems, their synthesis, functionalization, and targetability for therapeutic modulation of bioenergetics, and metabolic reprogramming of the cancer microenvironment. We highlight the potential of nanosystems for enhanced chemotherapeutic success emphasizing the questions that remain unanswered.

show abstract

Doxorubicin-loaded micelles in tumor cell-specific chemotherapy

Cited by 24 publications

References 166 publications

Smart design of a therapeutic nanoplatform for mitochondria-targeted copper-depletion therapy combined with chemotherapy

Smart design of a therapeutic nanoplatform for mitochondria-targeted copper-depletion therapy combined with chemotherapy

T Cell and Natural Killer Cell Membrane-Camouflaged Nanoparticles for Cancer and Viral Therapies

Cancer Bioenergetics and Tumor Microenvironments—Enhancing Chemotherapeutics and Targeting Resistant Niches through Nanosystems

Contact Info

Product

Resources

About